JPRN-jRCT2080220997未知2 期
Phase 2 study of RK-023 patients with androgenetic alopecia (male pattern baldness) -A study for safety and preliminary estimation of hair re-growth in male subjects with androgenetic alopecia treated for 13 weeks with RK-023
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 44age old（—）
- 性别
- Male
入选标准
- •Men aged between 20 and 44 years with an androgenetic alopecia rated as Takashima modified classification of Norwood-Hamiltonstage, IIv, IIIv and IV
排除标准
- •Subjects with the complication that treatment is required
研究者
相似试验
进行中（未招募）
Unknown
Testing the addition of new treatments to standard treatment in prostate cancer that has spread to other areas of the bodyMetastatic hormone-sensitive prostate cancerCancerISRCTN66357938niversity College London4,914
终止
2 期
Phase II pre-operative study of Androgen Deprivation Therapy (Degarelix) and Erdafitinib in high-risk localized prostate cancer.Cancer - ProstateProstate CancerACTRN12618001061224Melbourne Health (The Royal Melbourne Hospital)9
进行中（未招募）
不适用
A prospective randomised phase III study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer. - GETUG-AFU 21EUCTR2012-000142-35-ITICANCER916
进行中（未招募）
1 期
_metastatic hormone-naïve prostate cancerMedDRA version: 27.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000142-35-IEICANCER1,168
进行中（未招募）
不适用
A prospective randomised phase III study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.EUCTR2012-000142-35-FRICANCER916